Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CTP-656 (Deutivacaftor) in Cystic Fibrosis with Gating Mutations
NCT02971839Phase 2Terminated
- Sponsor
- Vertex Pharmaceuticals
- Start
- Dec 2016
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of deutivacaftor in cystic fibrosis (CF) (5 arms), sponsored by Vertex Pharmaceuticals. Primary endpoint: Change From Baseline in Sweat Chloride at Day 28. Started Dec 2016; status: terminated.
02
Drugs
deutivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT02971839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02971839.